Neophyr (Nitric Oxide)

Nitric oxide activates soluble guanylate cyclase in the smooth muscle of pulmonary vessels, raising cyclic GMP levels. The increased cGMP causes smooth‑muscle relaxation, leading to selective vasodilation of the lungs without significant systemic blood pressure changes, thereby improving ventilation‑perfusion matching.

The prescribed dose of Neophyr is determined by the treating physician based on the patient’s clinical status, oxygenation targets, and response to therapy. Dosing is individualized and typically titrated using continuous monitoring of oxygen saturation and hemodynamic parameters.

Safety data for inhaled nitric oxide in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To order Neophyr, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Neophyr delivers nitric oxide directly to the lungs, providing rapid and selective pulmonary vasodilation, whereas systemic vasodilators affect both pulmonary and systemic circulation, potentially causing broader hypotension. Inhaled nitric oxide offers precise control of pulmonary pressure with fewer systemic side effects.

Neophyr cylinders should be stored at ambient temperature, away from direct sunlight and heat sources. Keep the cylinder in its original packaging, ensure the valve is closed when not in use, and follow local regulations for medical gas storage and transport.

Neophyr is administered via a calibrated inhalation system that mixes the gas with the patient’s ventilatory circuit. The delivery device allows precise control of concentration, typically expressed in parts per million (ppm), and continuous monitoring is required throughout therapy.

The most serious risks include severe hypotension, significant methemoglobinemia that impairs oxygen delivery, and toxic nitrogen dioxide formation if concentrations are not properly controlled. Prompt recognition and management of these events are essential to ensure patient safety.

Neophyr should be avoided in patients with known hypersensitivity to nitric oxide, severe anemia, or those who cannot be closely monitored for methemoglobin levels and blood pressure. Contraindications are determined by the prescribing clinician based on individual patient factors.